multi-specific nanobody therapeutics (Ablynx/Novo Nordisk)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemulti-specific nanobody therapeutics (Ablynx/Novo Nordisk)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumDenmark

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAblynx Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovo Nordisk A/S Ablynx Nv

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A